Net Income

A new AI-designed vaccine, TG4050, has prevented relapse in all head and neck cancer patients in a key trial, signaling a breakthrough in personalized medicine.

AS Tallinna Sadam reports robust 2025 results, with a major jump in liquid bulk cargo and a strong rebound in cruise tourism signaling regional recovery.

As Valneva meets investors, all eyes are on its pivotal Lyme disease vaccine data, a potential game-changer for public health and the company's future.

Ventyx Biosciences is under investigation for misleading investors after a trial delay caused a 15% stock drop, even as a pharma giant moves to acquire it.

Boston's Moody Aldrich Partners commits $600M to London's SCIO Capital, a major validation of specialized asset-backed lending in Europe's booming market.

The P&C insurance tech leader leverages its strong cash position for a massive buyback, signaling confidence amid its successful cloud transformation.

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.

Amid soaring investor demand, Clearway Energy's oversubscribed bond offering provides critical capital to refinance debt and accelerate its US renewable projects.

With its radical solar car on the line, Aptera appoints a VW and BMW veteran as Chairman. Can traditional auto expertise finally launch a new era of efficiency?

With a new CEO from Illumina and Exact Sciences, Quanterix signals a strategic shift from tech development to aggressive market and clinical expansion.

Kimball Electronics announces a major medical facility in Indianapolis and a rebrand to Kimball Solutions, a strategic pivot into the high-growth life sciences market.

Operational failures at a key Texas plant and a sudden drop in chlorine demand force chemical giant Olin Corp. to drastically cut its Q4 earnings forecast.

With its Q4 earnings approaching, all eyes are on Federal Realty to see if its premium retail strategy can sustain its record dividend amid market shifts.

Alessa Therapeutics’ rice-sized implant, Enolen, earns FDA Fast Track, promising a new era for prostate cancer therapy without debilitating side effects.

With a $200M facility, BlackOpal's GemStone uses blockchain to offer institutional investors high-yield Brazilian assets without the traditional credit risk.

MiNK Therapeutics and UW–Madison launch a trial for an 'off-the-shelf' cell therapy, aiming to prevent deadly Graft-Versus-Host Disease (GvHD).

A new report reveals Canada's rail sector hit record safety, invested $4.5B, and grew its high-paying workforce, proving its essential economic role.

The pan-European exchange reports a year-over-year increase in December trading, with focus shifting to the impact of its recent Athens market acquisition.

After 13 years of refining its model, the luxury hair extension salon is partnering with a top developer to launch its specialized concept nationwide.

Singapore's Temasek injects another $150M into Roc360's REIT, highlighting a major institutional shift to real estate debt to fix America's aging houses.